News

The FDA is considering the approval of the Novavax COVID-19 booster after delays amid controversy over its non-mRNA design.
Novavax (NVAX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...
Vaccine maker Novavax's shares plunged nearly 20% at market close on Thursday, after Health and Human Services Secretary ...
Brad Smith outlines the top stories on Wall Street as part of Yahoo Finance's Market Minute. Vertiv Holdings (VRT) stock is ...